ReviewCancer treatment and research2026
Biomarkers of Cancer Metabolism and Therapeutic Response.
Review in Cancer treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insight into the metabolic reprogramming of cancer cells provides not only an understanding of the biology of the tumor but also novel biomarkers for diagnosis, prognosis, and therapy response monitoring. Cellular differentiation of tumors can be characterized by enhanced glycolysis, which is in accordance with changes in mitochondrial function and nutritional utilization. Elevated blood lactate and some amino acids have also been linked to tumor malignancy and unfavorable prognosis. Recent technologies, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), have advanced the detection of metabolic biomarkers. These methodologies enable the comprehensive metabolic profiling of tumor tissues and body fluids, which can identify specific metabolites with the potential to be used as biomarkers. In addition, the combination of genomics and proteomics with metabolomics has offered enhanced insights into cancer metabolism and has revealed the potential for the discovery of new therapeutic targets. They have also recognized the possibility of employing noninvasive imaging methods, such as positron emission tomography using radioactively labeled metabolites, to image tumor metabolism in real time. Such imaging modalities have the potential for delivering dynamic images of metabolic events occurring during treatment and offer a potent tool for monitoring treatment response and adapting the treatment plan accordingly.This book chapter discusses the status of cancer metabolic biomarkers and their discovery from the laboratory to clinical application potential.
Indexed as
Identifiers
42144526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.